TEST:

Prosigna™ Breast Cancer Prognostic Gene Signature Assay

Using the HIPPO interpretability method, we found that tumor regions were necessary and sufficient for high-risk predictions, and we identified candidate tissue biomarkers of recurrence. These results highlight the promise of interpretable, histology-based risk models in precision oncology.

RNA-based breast cancer subtyping suggests TP53 refines breast cancer etiologic heterogeneity in a sub-Saharan African population. The high prevalence of aggressive, mostly TP53-mutant tumors in this population underscores the need for further studies to clarify etiologic heterogeneity.

The results from the single-cell and deconvolution analyses confirmed subtype-specific immune microenvironments, which also allowed us to observe increased levels of natural killer (NK) and CD8+ T cells in Her2-enriched and Basal-like subtypes. In conclusion, our findings demonstrate significant differences in the immune tumor microenvironment between the established breast cancer molecular subtypes.

P2, N=671, Active, not recruiting, Dana-Farber Cancer Institute | Trial primary completion date: Dec 2025 --> May 2026

P2, N=5, Terminated, Fundacio Clinic Barcelona | N=17 --> 5 | Recruiting --> Terminated; The study was prematurely halted primarily due to low patient accrual. Despite efforts to optimize recruitment, the enrollment rate remained insufficient to meet the predefined targets, and continuation was deemed unfeasible

This work presents a novel and modular framework for simulating spinal cord atrophy data using digital phantoms, offering a controlled setting for testing spinal cord analysis pipelines. As the simulated atrophy may over-simplify in vivo conditions, future research will focus on enhancing the realism of the synthetic dataset by simulating additional pathologies, thus improving its application for evaluating spinal cord atrophy in clinical and research contexts.

P2, N=1260, Recruiting, MedSIR | Active, not recruiting --> Recruiting

Moreover, BC cells with high MNAI increased sensitivity to microtubule-targeting agents such as docetaxel, paclitaxel, and ixabepilone but increased resistance to tamoxifen, AKT1/2 inhibitors, and mTOR inhibitors. Consistent with these findings, analysis of 16 clinical trial cohorts revealed that patients with high MNAI achieved higher pathological complete response rates to taxane-containing and ixabepilone-based therapies. Our findings demonstrate the MNAI as a clinically actionable biomarker that can refine risk stratification and guide the selection of targeted or chemotherapy regimens, advancing precision medicine in BC management.

Immune-strong status correlated with improved DFS and OS in stage IIB-III patients (DFS, p = 0.029; OS, p = 0.003), and was associated with higher TILs (p = 0.015) and PD-L1 expression on tumor cells (p = 0.022). Multigene-based assessment of molecular subtype and immune status provides important prognostic insight into TNBC and may guide adjuvant treatment decisions, particularly in non-basal-like subtypes.

Disparities in MBC burden persist after adjustment for individual- and community-level healthcare access. Reducing burden of MBC in Black women necessitates simultaneous targeting of biological and access to care factors.

TILs and immune signatures showed a significant weak-to-moderate positive correlation with the basal-like signature. HR + /HER2- BCs that display both features of biological aggressiveness and enhanced immunogenicity may represent ideal candidates for the combination of ICI and chemotherapy.

Comprehensive documentation, including a vignette and user manual, supports effective application, while a dedicated tools portal provides installation instructions, frequently asked questions, and updates. The package is accessible at https://CRAN.R-project.org/package=PCAPAM50, with additional resources available at https://www.wriwindber.org/tools-portal/pcapam50/.